JP2025513489A - Ｃｘｃｒ４標的化合物、およびその作製方法、およびその使用方法 - Google Patents

Ｃｘｃｒ４標的化合物、およびその作製方法、およびその使用方法 Download PDF

Info

Publication number
JP2025513489A
JP2025513489A JP2024562169A JP2024562169A JP2025513489A JP 2025513489 A JP2025513489 A JP 2025513489A JP 2024562169 A JP2024562169 A JP 2024562169A JP 2024562169 A JP2024562169 A JP 2024562169A JP 2025513489 A JP2025513489 A JP 2025513489A
Authority
JP
Japan
Prior art keywords
residue
lys
compound
independently
forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024562169A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025513489A5 (https=
Inventor
ベナール，フランソワ
リン，クオ－シュヤン
リー リィ，リー
ジャン，ジョンシン
クォン，ダニエル
ペラン，ダヴィド
トドロヴィチ，ミハイロ
ラウ，ジョセフ
ライ，サムソン
クオ，ショウ－ティン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Provincial Health Services Authority
Original Assignee
Provincial Health Services Authority
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provincial Health Services Authority filed Critical Provincial Health Services Authority
Publication of JP2025513489A publication Critical patent/JP2025513489A/ja
Publication of JP2025513489A5 publication Critical patent/JP2025513489A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2024562169A 2022-04-20 2023-04-20 Ｃｘｃｒ４標的化合物、およびその作製方法、およびその使用方法 Pending JP2025513489A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263332885P 2022-04-20 2022-04-20
US63/332,885 2022-04-20
PCT/CA2023/050538 WO2023201435A1 (en) 2022-04-20 2023-04-20 Cxcr4-targeting compounds, and methods of making and using the same

Publications (2)

Publication Number Publication Date
JP2025513489A true JP2025513489A (ja) 2025-04-24
JP2025513489A5 JP2025513489A5 (https=) 2026-04-28

Family

ID=88418769

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024562169A Pending JP2025513489A (ja) 2022-04-20 2023-04-20 Ｃｘｃｒ４標的化合物、およびその作製方法、およびその使用方法

Country Status (7)

Country Link
US (1) US20250242064A1 (https=)
EP (1) EP4511384A1 (https=)
JP (1) JP2025513489A (https=)
CN (1) CN119325480A (https=)
AU (1) AU2023257191A1 (https=)
CA (1) CA3249424A1 (https=)
WO (1) WO2023201435A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025218761A1 (zh) * 2024-04-17 2025-10-23 晶核生物医药科技(上海)有限公司 环状肽类化合物、其药物组合物及其应用
CN120137854B (zh) * 2025-05-13 2025-09-23 中国农业大学 一种具有广泛pH适应性的有机磷矿化复合菌群及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2377579A1 (en) * 2007-05-30 2011-10-19 Eli Lilly and Company Cyclic peptide CXCR4 antagonists
KR20230145543A (ko) * 2017-09-05 2023-10-17 메인라인 바이오사이언스 고친화성 cxcr4 선택적 결합 콘쥬게이트 및 그 사용 방법
JP2021165234A (ja) * 2018-07-03 2021-10-14 富士フイルム富山化学株式会社 Ｃｘｃｒ４結合性化合物もしくはその塩またはそれらと金属との錯体
US20220218852A1 (en) * 2019-04-18 2022-07-14 Provincial Health Services Authority Novel radiolabelled cxcr4-targeting compounds for diagnosis and therapy
JP2023549469A (ja) * 2020-10-21 2023-11-27 プロビンシャル・ヘルス・サービシーズ・オーソリティ 新規ｃｘｃｒ４標的化合物

Also Published As

Publication number Publication date
CN119325480A (zh) 2025-01-17
EP4511384A1 (en) 2025-02-26
WO2023201435A1 (en) 2023-10-26
CA3249424A1 (en) 2023-10-26
WO2023201435A8 (en) 2023-12-28
US20250242064A1 (en) 2025-07-31
AU2023257191A1 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
JP7618599B2 (ja) 前立腺特異的膜抗原を標的とする放射性標識化合物
CA3118223A1 (en) Dual mode 18f-labelled theranostic compounds and uses thereof
AU2019273132B2 (en) Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy
JP7541532B2 (ja) 診断及び治療のための新規な放射性標識されたｃｘｃｒ４を標的とする化合物
JP2023549469A (ja) 新規ｃｘｃｒ４標的化合物
AU2020257786B2 (en) Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer
CN113454098A (zh) 用于胃泌素释放肽受体(grpr)的体内成像和治疗grpr相关病症的放射性标记蛙皮素衍生化合物
JP2025507971A (ja) 前立腺特異的膜抗原を標的とする放射性標識化合物
JP2025513489A (ja) Ｃｘｃｒ４標的化合物、およびその作製方法、およびその使用方法
CN104780944A (zh) 用于癌症和其它疾病的医学成像的靶向缓激肽受体b1的组合物
US20250195702A1 (en) Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
TW202541853A (zh) 增濃且安定之放射配體治療調製劑及包含彼之醫藥組成物
US12616761B2 (en) CXCR4-targeting compounds
WO2025054727A1 (en) Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
WO2025111712A1 (en) Gastrin-releasing peptide receptor (grpr)-targeted compounds and uses thereof
WO2025147774A1 (en) Compositions targeting bradykinin receptor b1 for medical imaging and treatment of cancer and other disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260420

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260420